Systemic cholesterol and lipid metabolism is tightly regulated through the interplay and cross‐communication of numerous pathways across a range of tissues and organs.[1] Among these, the hepatic SREBP2 (sterol regulatory element‐binding protein 2)‐mediated cholesterol/fatty acid biosynthesis and peripheral LPL (lipoprotein lipase)‐mediated lipolysis of triglyceride (TG)‐rich lipoproteins are two major pathways that govern systemic cholesterol/lipid homeostasis.[2, 3] Dysregulation of these pathways is associated with a variety of cardiovascular and metabolic diseases.[4, 5]. The gene discussed is LPL; the disease is metabolic disease.